Daniela Tardito

List of Publications by Year
in descending order

47	2,663	172457 29	233421 45
papers	citations	h-index	g-index

54	54	54	3380
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	miR-9-5p is involved in the rescue of stress-dependent dendritic shortening of hippocampal pyramidal neurons induced by acute antidepressant treatment with ketamine. Neurobiology of Stress, 2021, 15, 100381.	4.0	20
2	Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments. Genes, 2020, 11, 1089.	2.4	17
3	Global epigenetic analysis of BDNF Val66Met mice hippocampus reveals changes in dendrite and spine remodeling genes. Hippocampus, 2018, 28, 783-795.	1.9	13
4	Peripheral whole blood microRNA alterations in major depression and bipolar disorder. Journal of Affective Disorders, 2016, 200, 250-258.	4.1	138
5	Time-dependent activation of MAPK/Erk1/2 and Akt/GSK3 cascades: modulation by agomelatine. BMC Neuroscience, 2014, 15, 119.	1.9	9
6	Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Frontiers in Cellular Neuroscience, 2014, 8, 75.	3.7	100
7	P.2.a.006 Agomelatine and fluoxetine induce different and time-dependent modulation of rat hippocampal miRNome. European Neuropsychopharmacology, 2014, 24, S364.	0.7	1
8	Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes. BMC Neuroscience, 2013, 14, 75.	1.9	31
9	Lost in translation. New unexplored avenues for neuropsychopharmacology: epigenetics and microRNAs. Expert Opinion on Investigational Drugs, 2013, 22, 217-233.	4.1	32
10	P.3.010 Time-dependent effects of antidepressant treatments on miRNome expression profile in hippocampus of rats. European Neuropsychopharmacology, 2013, 23, S65.	0.7	0
11	Blood microRNA changes in depressed patients during antidepressant treatment. European Neuropsychopharmacology, 2013, 23, 602-611.	0.7	197
12	Physical Exercise and Antidepressants Enhance BDNF Targeting in Hippocampal CA3 Dendrites: Further Evidence of a Spatial Code for BDNF Splice Variants. Neuropsychopharmacology, 2012, 37, 1600-1611.	5.4	96
13	Synergistic mechanisms involved in the antidepressant effects of agomelatine. European Neuropsychopharmacology, 2012, 22, S482-S486.	0.7	42
14	Antidepressant Treatments Change 5-HT2C Receptor mRNA Expression in Rat Prefrontal/Frontal Cortex and Hippocampus. Neuropsychobiology, 2011, 63, 160-168.	1.9	38
15	Mode of action of agomelatine: Synergy between melatonergic and 5-HT_{2C}receptors. World Journal of Biological Psychiatry, 2011, 12, 574-587.	2.6	262
16	Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochemistry International, 2011, 59, 896-905.	3.8	61
17	P.1.022 Epigenetic modifications in transgenic mouse with human polymorphism (Val66Met) of BDNF gene. European Neuropsychopharmacology, 2011, 21, S19-S20.	0.7	0
18	Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 2011, 116, 1028-1042.	3.9	63

#	Article	IF	Citations
19	Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression. Journal of Psychiatric Research, 2010, 44, 511-520.	3.1	50
20	Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways. BMC Neuroscience, 2010, 11, 68.	1.9	50
21	Acute Stress Increases Depolarization-Evoked Glutamate Release in the Rat Prefrontal/Frontal Cortex: The Dampening Action of Antidepressants. PLoS ONE, 2010, 5, e8566.	2.5	217
22	Remodelling by early-life stress of NMDA receptor-dependent synaptic plasticity in a geneâ€“environment rat model of depression. International Journal of Neuropsychopharmacology, 2009, 12, 553.	2.1	63
23	Early induction of CREB activation and CREB-regulating signalling by antidepressants. International Journal of Neuropsychopharmacology, 2009, 12, 1367.	2.1	40
24	Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. BMC Neuroscience, 2009, 10, 48.	1.9	53
25	Time-dependent biphasic modulation of human BDNF by antidepressants in neuroblastoma cells. BMC Neuroscience, 2008, 9, 61.	1.9	25
26	Synaptoproteomics of Existing and new Animal Models of Depression. , 2008, , 185-202.		0
27	Chronic Antidepressants Induce Redistribution and Differential Activation of Î±CaM Kinase II between Presynaptic Compartments. Neuropsychopharmacology, 2007, 32, 2511-2519.	5.4	46
28	Reduced CREB phosphorylation after chronic lithium treatment is associated with down-regulation of CaM kinase IV in rat hippocampus. International Journal of Neuropsychopharmacology, 2007, 10, 491.	2.1	22
29	Long-term soluble Aî²1â€“40 activates CaM kinase II in organotypic hippocampal cultures. Neurobiology of Aging, 2007, 28, 1388-1395.	3.1	10
30	P.1.21 Time-dependent and sequential modulation of signaling, CREB activation and BDNF expression induced by antidepressants. European Neuropsychopharmacology, 2007, 17, S18-S19.	0.7	0
31	Signaling Pathways Regulating Gene Expression, Neuroplasticity, and Neurotrophic Mechanisms in the Action of Antidepressants: A Critical Overview. Pharmacological Reviews, 2006, 58, 115-134.	16.0	270
32	Regulation of Editing and Expression of Glutamate Î±-Amino-Propionic-Acid (AMPA)/Kainate Receptors by Antidepressant Drugs. Biological Psychiatry, 2006, 59, 713-720.	1.3	92
33	Selective Phosphorylation of Nuclear CREB by Fluoxetine is Linked to Activation of CaM Kinase IV and MAP Kinase Cascades. Neuropsychopharmacology, 2004, 29, 1831-1840.	5.4	171
34	Expression and phosphorylation of Î´-CaM kinase II in cultured Alzheimer fibroblasts. Neurobiology of Aging, 2004, 25, 1187-1196.	3.1	7
35	Protein kinase A activity in platelets from patients with bipolar disorder. Journal of Affective Disorders, 2003, 76, 249-253.	4.1	22
36	cAMP signaling pathway in depressed patients with psychotic features. Molecular Psychiatry, 2002, 7, 208-212.	7.9	34

#	Article	IF	Citations
37	The protein kinase A in platelets from patients with panic disorder. European Neuropsychopharmacology, 2002, 12, 483-487.	0.7	4
38	THE INTERFACE BETWEEN DEPRESSION AND CEREBROVASCULAR DISEASEâ€"SOME HOPE BUT NO HYPE. Clinical and Experimental Hypertension, 2002, 24, 639-646.	1.3	2
39	The cAMP-dependent protein kinase substrate Rap1 in platelets from patients with obsessive compulsive disorder or schizophrenia. European Neuropsychopharmacology, 2001, 11, 221-225.	0.7	14
40	Implications of the cAMP Signaling Pathway in Psychiatric Disorders: A Systematic Review of the Evidence. CNS Spectrums, 2001, 6, 294-305.	1.2	8
41	Protein kinase A and Rap1 levels in platelets of untreated patients with major depression. Molecular Psychiatry, 2001, 6, 44-49.	7.9	52
42	Altered cAMP-Dependent Protein Kinase A in Platelets of Patients With Obsessive-Compulsive Disorder. American Journal of Psychiatry, 2000, 157, 284-286.	7.2	21
43	Abnormalities of cAMP signaling in affective disorders: implications for pathophysiology and treatment. Bipolar Disorders, 2000, 2, 27-36.	1.9	58
44	Abnormal Levels of cAMP-dependent Protein Kinase Regulatory Subunits in Platelets from Schizophrenic Patients. Neuropsychopharmacology, 2000, 23, 216-219.	5.4	36
45	Altered Rap1 endogenous phosphorylation and levels in platelets from patients with bipolar disorder. Journal of Psychiatric Research, 2000, 34, 99-104.	3.1	30
46	Abnormalities of Cyclic Adenosine Monophosphate Signaling in Platelets From Untreated Patients With Bipolar Disorder. Archives of General Psychiatry, 1999, 56, 248.	12.3	65
47	Effects of Lithium on cAMP-Dependent Protein Kinase in Rat Brain. Neuropsychopharmacology, 1998, 19, 233-240.	5.4	32